TransMedics Group (NASDAQ:TMDX) Rating Lowered to Hold at Zacks Research

Key Points

• TransMedics Group's stock rating was downgraded from "strong-buy" to "hold" by Zacks Research, signaling a shift in analyst sentiment.
• Despite the downgrade, the stock maintains a consensus rating of "Moderate Buy" with an average target price of $125.40.
• TransMedics recently reported earnings of $0.92 EPS, significantly surpassing the consensus estimate of $0.48, and demonstrated a 37.7% year-over-year revenue growth.

TransMedics Group (NASDAQ:TMDX - Get Free Report) was downgraded by equities research analysts at Zacks Research from a "strong-buy" rating to a "hold" rating in a research note issued to investors on Monday,Zacks.com reports.

TMDX has been the subject of a number of other research reports. Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a research report on Monday, August 25th. Wall Street Zen lowered TransMedics Group from a "buy" rating to a "hold" rating in a research report on Saturday, August 30th. Morgan Stanley raised their price objective on TransMedics Group from $115.00 to $123.00 and gave the company an "equal weight" rating in a research report on Friday, August 1st. Weiss Ratings reaffirmed a "hold (c)" rating on shares of TransMedics Group in a research report on Saturday, September 27th. Finally, Canaccord Genuity Group raised their price objective on TransMedics Group from $129.00 to $142.00 and gave the company a "buy" rating in a research report on Tuesday, July 15th. Six investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $125.40.

TransMedics Group Trading Up 1.1%

TMDX opened at $115.18 on Monday. The stock has a market cap of $3.93 billion, a PE ratio of 59.68 and a beta of 2.08. The company has a quick ratio of 9.17, a current ratio of 9.86 and a debt-to-equity ratio of 1.61. The business has a 50 day moving average of $117.39 and a 200-day moving average of $111.24. TransMedics Group has a 52 week low of $55.00 and a 52 week high of $145.50.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its earnings results on Wednesday, July 30th. The company reported $0.92 EPS for the quarter, beating analysts' consensus estimates of $0.48 by $0.44. The company had revenue of $157.37 million during the quarter, compared to analysts' expectations of $146.64 million. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%.The firm's revenue for the quarter was up 37.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.35 EPS. TransMedics Group has set its FY 2025 guidance at EPS. Equities research analysts predict that TransMedics Group will post 1 earnings per share for the current fiscal year.

Institutional Trading of TransMedics Group

A number of institutional investors and hedge funds have recently modified their holdings of TMDX. NBC Securities Inc. bought a new stake in shares of TransMedics Group in the 1st quarter worth $25,000. GAMMA Investing LLC increased its holdings in shares of TransMedics Group by 551.7% in the 1st quarter. GAMMA Investing LLC now owns 1,564 shares of the company's stock worth $105,000 after purchasing an additional 1,324 shares in the last quarter. SG Americas Securities LLC increased its holdings in shares of TransMedics Group by 132.2% in the 1st quarter. SG Americas Securities LLC now owns 14,126 shares of the company's stock worth $950,000 after purchasing an additional 8,043 shares in the last quarter. Campbell Newman Asset Management Inc. boosted its stake in shares of TransMedics Group by 1.4% in the 1st quarter. Campbell Newman Asset Management Inc. now owns 11,619 shares of the company's stock worth $782,000 after buying an additional 166 shares during the last quarter. Finally, Janney Montgomery Scott LLC boosted its stake in shares of TransMedics Group by 129.9% in the 1st quarter. Janney Montgomery Scott LLC now owns 8,799 shares of the company's stock worth $592,000 after buying an additional 4,972 shares during the last quarter. Institutional investors own 99.67% of the company's stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.